Good MorningEquity investors got a healthy dose of reality on Friday when Apple announced it was closing stores in some hard-hit stats. Economic reopenings in states like Florida and Arizona have resulted in record new COVID cases sparking the companies decision. A total of eleven stores including those in North Carolina and South Carolina are part of the closing and more could follow in the coming days.
The news from Apple highlights a growing fear, the fear that COVID will cause another round of economic shutdown in the U.S. The S&P 500 responded by reversing gains and moving lower by roughly 1.0%. The takeaways are that however dire Friday’s news may seem, the S&P 500 still closed up for the week and poised for gains in the weeks to come. An increase in the number of COVID cases won’t hold the market back so long as the economic data is improving.
Featured: Up to 93.2% accuracy trading before the open? (WealthPress) 
|
Markets | | |
There’s no such thing as guaranteed gains the stock market, but investing in a strong dividend-paying company offers relative safety and nice income regardless of market volatility. That’s why many investors are focused on finding the best dividend stocks in the market, particularly in... Read the Full Story |
|
From Our PartnersThere's a huge new tech trend coming to your hometown - which could make you a small fortune over the next few years. And today we're revealing the name and stock ticker symbol of Whitney's favorite way to make money from this trend. | | You get his top pick for free, right here. |
|
Markets | | | Beating The Estimates, And The Outlook Is Good
Smith & Wesson (SWBI) just reported a blow-out quarter, literally, and has the stock positioned for longer-term gains. The company's name was recently changed from American Outdoor Brands to Smith & Wesson Brands is the same great firearms comp... Read the Full Story |
|
Stocks | | | Growth, It’s Where You Find It
It is no secret that Q2 earnings growth among S&P 500 (SPY) companies is going to be bad. Really bad. Like in the range of -50% bad and that is no joke. Despite this, there is an outlook for growth within the market providing you know where to look. The seco... Read the Full Story |
|
|
Stocks | | | As had been the case for many years coming into 2020, discount retail department stores were easily outperforming traditional brick and mortar names when the coronavirus pandemic hit. But the virus and its economic fallout doesn’t choose who it affects or how. All non-essential businesses were... Read the Full Story |
|
Markets | | |
So one of the biggest questions post-pandemic for a lot of people out there was “But what effect does all this have on Prime Day?”. Amazon (NASDAQ: AMZN) runs its premiere non-Black-Friday sale every year around this time, but with the pandemic running roughshod over all our traditions... Read the Full Story |
|
From Our PartnersThe key to being consistently profitable as a trader is to focus on high-probability trades. And in this powerful eBook by Dave Acquino, titled The Ultimate Income Trading System, you'll see exactly how Dave and so many of his students do just that. They make 4%, 5% or 6% on each trade and they're in the trade for just 11 hours. | | CLICK HERE for instant access. |
|
The Early Bird Stock Of The Day Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. | | View Today's Stock Pick |
|
